Member News

LBA Angel Syndicate closes £250k seed round into Orbel Health Limited

8 September 2011

Early stage London based Healthcare company Orbel Health Limited has closed its £250k round with the entire investment raised from an LBA syndicate which included sector specialists. The company has developed a unique patented hand disinfector dispenser to tackle all the problems associated with hand hygiene. The seed funding will allow the company to further develop and trial its product which has already caught the attention of a major international company involved in the b2c markets.

LBA Angels close £230k seed angel funding into Momentum Bioscience Limited

5 September 2011

Early Stage Reading based Medtech company Momentum Bioscience Limited which is Chaired by David Evans, AIM Chairman of the year in 2009, has successfully closed a £230k round, including £180k from LBA investors. Momentum Bioscience also becomes the second investment made by the LBA EIS RoundTable Syndicate Fund 2011.

Pavegen Systems early stage funding round cornerstoned by £210k of LBA angel investment

2 September 2011
Early stage Cleantech business Pavegen Systems has successfully completed its first external funding round including £210k invested by LBA members, led by Mark Randall of Renaissance Capital Partners who were introduced to the Company at LBA’s Company Presentation Event on 12 July 2011.

Pavegen Systems, founded in 2009 by an engineering graduate of Loughborough University, has developed an off-grid technology which converts the kinetic energy from footsteps into electricity to be stored

Eykona Technologies Closes Further Funding Round

30 August 2011
Eykona Technologies Ltd, the Oxford based 3D imaging Medtech company, has closed another over-subscribed investment round. The Series B round of £1.25m was cornerstoned by MTI Partners’ UMIP Premier Fund and Parkwalk Advisors, who have both increased their holding, with included follow on investment from LBA.

Scour Prevention Systems secures £100k LBA investment to close its £350k round

3 August 2011

LBA are delighted to announce that Scour Prevention Systems Ltd (SPS) has successfully raised c. £350k. The company presented to LBA on 26 May 2011 looking for just £100k to close its funding round which included a £100k grant, and received an overwhelming response from our network, with firm offers for significantly more than this. SPS ultimately accepted £100k from two hands on value adding LBA investors.

LBA secures double honours at the BBAA National Awards 2011 with Syrinix and ipadio

5 July 2011

LBA are delighted to have been honoured with two awards at the BBAA National Awards 2011 which took place on 30 June, for our investments in innovating businesses over the last 12 months. Syrinix was awarded Angel Clean Tech Investment of the Year, and ipadio was recognised as Angel Mobile Investment of the Year. Both companies not only received investment from LBA investors, but also secured investment from the first LBA EIS RoundTable Fund. secures £100k with LBA investment

30 June 2011, the ‘Groupspaces for amateur football’, has secured a £100k first round, including significant funding from 2 LBA investors.

London Business Angels announce new £420k EIS RoundTable Syndicate Fund

1 June 2011

London Business Angels (LBA) are delighted to announce that our new  £420,000 HMRC Approved EIS RoundTable Syndicate Fund is open for business with all cash invested now held by the Fund's Registrars.

LBA secures c. £100k first round funding for social shopping website

14 March 2011

LBA are delighted to announce that have secured a c. £100k first round of angel funding anchored by a syndicate of LBA investors.

LBA anchors a £250k investment round in The Electrospinning Company

9 March 2011

The Electrospinning Company Limited is a nanofibre innovation and development company that was set up by the Rutherford Appleton Laboratory in Oxford in 2008 in order to use the electrospinning process to manufacture nanofibre structures and scaffolds for the biotech industry and in particular the rapidly emerging stem cell therapy sector.